Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × dolasetron × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1 Neoplasms 1 Nausea 1

Interventions

pembrolizumab 876 Carboplatin 822 Paclitaxel 805 Gemcitabine 673 Cisplatin 650 Docetaxel 610 Bevacizumab 545 Nivolumab 431 Pemetrexed 423 Cyclophosphamide 409 Capecitabine 403 Fluorouracil 347 Dexamethasone 341 Rituximab 339 Oxaliplatin 293 Injections 287 atezolizumab 270 Trastuzumab 264 Cetuximab 245 Leucovorin 240 Prednisone 225 Irinotecan 225 130-nm albumin-bound paclitaxel 221 Doxorubicin 214 Ipilimumab 201 Lenalidomide 197 Fulvestrant 192 fludarabine 182 durvalumab 180 Drug Therapy 174

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed

494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡